AsyncHealth
OperatingAsyncHealth, Inc.
Healthcare · Pebble Beach, CA
AsyncHealth has developed and launched its HIPAA-compliant software, "Async," which has been used in clinical environments. With $7M in NIH grants, an exclusive IP agreement and a patent-pending, three successful clinical trials involving 550 patients, 15 peer-reviewed publications and early customer traction, the company aims to begin generating revenue in 2025*.
Financials
FY2023–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Cap table
Share counts as of Apr 9, 2026| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Common Stock | 4,488,298 | 1 | 100.0% | $1.56Apr 2025 |
Principal holders% as the filing states it, Apr 9, 2026
- Peter Yellowlees2,700,000 Common Stock60.5%of company
- Steven Chan900,000 Common Stock20.2%of company
- Everyone else (not named in filings)19.3%
Sold to the crowd
- Reg CF · Apr 2025112,286 shares at $1.56$175.2K· 61 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
4 people
Peter Yellowlees, MD, is the CEO and founder of AsyncHealth. He is a psychiatrist with extensive experience in asynchronous mental health consultations, having led a research team in this field for over a decade. Through AsyncHealth, Dr. Yellowlees is working to commercialize asynchronous mental health consultation technologies.
Ms. Yellowlees, COO of AsyncHealth, has extensive experience in the health technology industry. She previously served as founder and CEO of HealthLinkNow, Inc., a telemedicine company that was acquired by a Fortune 500 company in 2016. Ms. Yellowlees has also held leadership roles at RoboPath, Inc. and the Medical Board of California, and has contributed to industry organizations such as the California Emerging Technology Fund and the American Telemedicine Association.
Bob Gregoire is the Chief Business Officer of AsyncHealth. He brings extensive experience leading organizations through transitions and growth initiatives. Bob is also the Founder and Chairman of CxORE, an advisory firm supporting organizations undergoing change. He previously founded and led a national outsourcing firm that was acquired by CH2M Hill (now Jacobs) and has served on various professional and community boards.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 1 annual reports (FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.